Urologix Announces Restructuring of Payment Obligations to Medtronic and Reports Preliminary Fiscal Year 2013 Revenue and Cash Results
July 01, 2013 09:00 ET
|
21st North Inc.
MINNEAPOLIS, July 1, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office BPH therapy, announces the restructuring of payment obligations to Medtronic related...
Urologix to Transfer From NASDAQ to the OTCQB Marketplace
June 05, 2013 16:00 ET
|
21st North Inc.
MINNEAPOLIS, June 5, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, announced today that its Board of Directors has authorized the transfer...
Urologix Reports Fiscal Year 2013 Third Quarter Results and Reaffirms Annual Guidance
May 01, 2013 16:00 ET
|
21st North Inc.
Third Quarter Summary
Third quarter revenue of $4.1 million
Quarter-end cash balance of $5.1 million
Guidance for fiscal year 2013 revenue reaffirmed at $16.0 million to $17.0...
Urologix Receives Extension From NASDAQ to Regain Compliance With Listing Requirements
April 17, 2013 17:00 ET
|
21st North Inc.
MINNEAPOLIS, April 17, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, announced today that the NASDAQ Hearings Panel (the "Panel") of The...
Urologix Announces Important Milestone in Prostiva(R) RF Therapy Licensing Agreement
April 08, 2013 09:00 ET
|
21st North Inc.
MINNEAPOLIS, April 8, 2013 (GLOBE NEWSWIRE) -- Urologix, Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, today announced that it has reached an important milestone in its licensing...
Urologix Reports Fiscal Year 2013 Second Quarter Results and Reaffirms Annual Guidance
February 05, 2013 16:00 ET
|
21st North Inc.
Executive Summary
Second quarter revenue reported at $4.4 million, up 9.7% sequentially.
Guidance for fiscal year 2013 revenue reaffirmed at $16.0 million to $17.0 million.
MINNEAPOLIS,...
Urologix Names Greg Fluet as New CEO
January 30, 2013 09:00 ET
|
21st North Inc.
MINNEAPOLIS, Jan. 30, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, announced today that its Board of Directors has appointed Greg Fluet...
Urologix Receives NASDAQ Notification Related to Minimum Bid Price Requirement
January 29, 2013 16:00 ET
|
21st North Inc.
MINNEAPOLIS, Jan. 29, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, announced today that it received a letter from The NASDAQ Stock Market...
Urologix Announces Leadership Change
November 20, 2012 09:00 ET
|
21st North Inc.
MINNEAPOLIS, Nov. 20, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced a...
Urologix Reports Fiscal Year 2013 First Quarter Results and Revises Annual Guidance
November 14, 2012 16:00 ET
|
21st North Inc.
First quarter revenue of $4.0 million, up 26.3% year-over-year
Cash balance increases to $5.3 million after completion of follow-on offering
Cooled ThermoTherapy reimbursement code...